ALSO NOTED: New doubts on Arcoxia; Pharmacopeia bullish on early data; Ammon retires from Endo; and much more...

> Raising fresh doubts about the prospects of Merck's Arcoxia when it goes in front of an FDA panel on Thursday, the agency released its opinion that the only NSAIDs that should be approved now would have to fill an unmet medical need where no safe alternative exists. Report

> Pharmacopeia Drug Discovery sounded a bullish note on early data for an experimental therapy for hypertension and diabetic nephropathy. Report

> Chutes & Ladders: Carol Ammon, the founder and chairwoman of Endo Pharmaceuticals, plans to retire and focus on philanthropy. Article

> The Medical University of South Carolina has begun construction of a new drug research facility. Report

> Orexigen Therapeutics has set the terms for its IPO at 6 million shares priced at $11 to $13 per share. Report

> J&J is recalling a prescription drug for fungal infections after finding fragments of glass in bottles of the therapy. Report

> Researchers at Duke University say that family members that smoked and drank coffee were less likely to develop Parkinson's disease. Report

> The NIAID will spend $23 million a year over the next seven years to establish a consortium of six research centers to investigate influenza viruses--including H5N1. Report

And Finally... GSK has turned to an auto company for research ideas. Report